key: cord-0843257-ghct340s
authors: Pawankar, Ruby; Thong, Bernard Yu‐Hor; Tiongco‐Recto, Marysia; Wang, Jiu‐Yao; Abdul Latiff, Amir Hamzah; Thien, Francis; Oh, Jae‐Won; Kamchaisatian, Wasu; Rengganis, Iris; Udwadia, Zarir F.; Dhar, Raja; Munkhbayarlakh, Sonomjamts; Narantsetseg, Logii; Le Pham, Duy; Leung, Ting Fan; Zhang, Luo
title: Asia‐Pacific perspectives on the COVID‐19 pandemic
date: 2021-05-18
journal: Allergy
DOI: 10.1111/all.14894
sha: 5e807bf31963235ab8e8839890066cf87d3c463a
doc_id: 843257
cord_uid: ghct340s

nan

comorbidities reported by respondents, where multiple responses were allowed. Asthma and obesity were only reported by 8.3%, respectively ( Figure S2 ).

National guidelines for COVID-19 were available in 84. 6% 

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. China

Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives -a report of the European Academy of Allergy and Clinical Immunology (EAACI)

Predictors of COVID-19 severity: a literature review

COVID-19 and asthma, the good or the bad?

COVID-19 Clinical trials: quality matters more than quantity

Management of allergic patients during the COVID-19 pandemic in Asia

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA position paper

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation

Additional supporting information may be found online in the Supporting Information section.